Econ and Finance - 14 Feb 2022

China OKs Pfizer COVID drug

Subscribe to keep reading.

Sign up to stay briefed on what the Chinese government is doing, thinking, and saying.

Already a subscriber? Log in.

On Friday, surprising news emerged from China's pharmaceutical regulator (NMPA):

Pfizer's COVID-19 treatment drug – Paxlovid – has received conditional approval to register in China.It's the first oral pill specifically developed for the disease to be cleared by regulators.

Business wheels ar...

Snuh-ohez.

Your subscription doesn't include access to this content. Upgrade your account to access.

Change your plan